Thanos Zomas, MD, from Takeda Oncology, discusses the 5-year long-term data analysis of the ECHELON-2 study, which was recently presented at EHA 2021.
The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018. It compared the efficacy and safety of brentuximab vedotin (Adcetris; A) in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCLs).
PTCLs are a diverse group of aggressive lymphomas that develop from T-cells and natural killer (NK) cells. PTCLs are a subtype of non-Hodgkin’s lymphoma.
The ECHELON-2 study demonstrated a significantly longer progression-free survival (PFS) and overall survival (OS) in patients receiving brentuximab vedotin+CHP. Median PFS was 48 months in the brentuximab vedotin+CHP group and 21 months in the CHOP group. Adverse events were similar between groups.
The 5-year follow-up data presented at EHA 2021 reaffirms these results, demonstrating that frontline treatment with A+CHP continues to provide clinically meaningful improvement in PFS and OS compared to CHOP. More specifically, frontline A+CHP continued to provide clinically meaningful improvements in PFS and OS vs CHOP, including sustained remission in 59% of re-treated patients with sALCL, as well as a manageable safety profile, including continued resolution or improvement of PN. As Dr. Zomas alludes to a manageable safety profile is particularly important as PTCL patients tend to be older than Hodgkin’s lymphoma patients.
For more information about peripheral T-cell lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/